Target Validation Information
TTD ID	T20973
Target Name	Cyclin-dependent kinase 5 (CDK5)
Type of Target	Patented-recorded
Drug Potency against Target	AT7519	Drug Info	IC50 = 13 nM	[5]
	R-roscovitine	Drug Info	IC50 = 270 nM	[5]
	SCH 727965	Drug Info	IC50 < 5 nM	[5]
	1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea	Drug Info	IC50 = 2990 nM	[2]
	3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one	Drug Info	IC50 = 1400 nM	[4]
	AZAKENPAULLONE	Drug Info	IC50 = 4200 nM	[1]
	KENPAULLONE	Drug Info	IC50 = 850 nM	[1]
	MANZAMINE A	Drug Info	IC50 = 1500 nM	[3]
	Thieno analogue of kenpaullone	Drug Info	IC50 = 4000 nM	[1]
References
REF 1	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
REF 2	Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorg Med Chem. 2007 Oct 15;15(20):6574-95.
REF 3	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405.
REF 4	Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5384-9.
REF 5	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.